Julian Rees, HOPO Therapeutics CEO (Credit: Majed Abolfazli)
HOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning research
HOPO Therapeutics scored a government contract for up to $226 million to develop an oral countermeasure against radiological threats and heavy metal poisoning.
The funding …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.